THERAPIX BIOSCI/S (NASDAQ:TRPX) Trading 19.4% Higher
Shares of THERAPIX BIOSCI/S (NASDAQ:TRPX) shot up 19.4% on Thursday . The company traded as high as $2.15 and last traded at $1.72, 1,299,000 shares traded hands during trading. An increase of 1,439% from the average session volume of 84,430 shares. The stock had previously closed at $1.44.
Separately, ValuEngine raised THERAPIX BIOSCI/S from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
The business has a fifty day simple moving average of $2.38 and a two-hundred day simple moving average of $2.60.
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Recommended Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for THERAPIX BIOSCI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for THERAPIX BIOSCI/S and related companies with MarketBeat.com's FREE daily email newsletter.